NOVA1 — NOVA Alternative Splicing Regulator 1
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NOVA1 — NOVA Alternative Splicing Regulator 1</th>
</tr>
<tr> [@raj2018]
<td class="label">Symbol</td> [@darnell2010]
<td><strong>NOVA1</strong></td> [@licatalosi2008]
</tr>
<tr>
<td class="label">Full Name</td>
<td>NOVA Alternative Splicing Regulator 1 (Neuro-Oncological Ventral Antigen 1)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>14q12</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/4857" target="_blank">4857</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139910" target="_blank">ENSG00000139910</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/602157" target="_blank">602157</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P51513" target="_blank">P51513</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), Paraneoplastic Opsoclonus-Myoclonus Ataxia (POMA)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>[Neurons](/entities/neurons) (hindbrain, ventral spinal cord, [hippocampus](/brain-regions/hippocampus), cortex)</td>
</tr>
</table>
NOVA1 — NOVA Alternative Splicing Regulator 1
Overview
NOVA1 (NOVA Alternative Splicing Regulator 1), originally identified as Neuro-Oncological Ventral Antigen 1, encodes a neuron-specific RNA-binding protein on chromosome 14q12 that is a master regulator of alternative splicing in the nervous system. NOVA1 was the first mammalian splicing factor identified through its role as the target autoantigen in paraneoplastic opsoclonus-myoclonus ataxia (POMA), a neurological autoimmune syndrome[@buckanovich1993].
NOVA1 regulates the alternative splicing of hundreds of pre-mRNAs encoding synaptic proteins, neurotransmitter receptors, ion channels, and cytoskeletal components. It binds YCAY motifs in pre-mRNA with high specificity, acting as a splicing enhancer or repressor depending on binding position relative to the regulated exon. Together with its paralog [NOVA2](/genes/nova2), NOVA1 orchestrates a neuron-specific splicing program essential for synaptic development, function, and plasticity[@ule2006].
Disruption of NOVA1-dependent splicing has been increasingly implicated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [ALS](/diseases/amyotrophic-lateral-sclerosis), where aberrant RNA processing contributes to synaptic dysfunction and neurodegeneration.
Gene Structure and Protein Products
Genomic Organization
The NOVA1 gene spans approximately 133 kb on chromosome 14q12, containing 8 exons. The gene itself is subject to alternative splicing, generating multiple isoforms with tissue-specific expression patterns[@jensen2000].
Protein Structure
The NOVA1 protein (512 amino acids) contains three KH (K-Homology) RNA-binding domains:
- KH1 domain (N-terminal): Contributes to RNA binding specificity
- KH2 domain (central): Primary RNA-binding domain; crystal structure reveals specific YCAY tetranucleotide recognition
- KH3 domain (C-terminal): Participates in RNA binding and protein-protein interactions
- Nuclear localization signal: Directs NOVA1 to the nucleus for co-transcriptional splicing regulation
- Dimerization domain: NOVA1 can form homodimers and heterodimers with [NOVA2](/genes/nova2)
RNA Binding Specificity
NOVA1 recognizes the YCAY motif (where Y = pyrimidine) in pre-mRNA through a well-characterized mechanism:
- KH2 domain makes base-specific contacts with YCAY elements
- Binding affinity increases with clusters of YCAY repeats
- Position of binding relative to the regulated exon determines splicing outcome:
- Upstream intronic binding: Typically promotes exon skipping
- Downstream intronic binding: Typically promotes exon inclusion
- This positional code is known as the "NOVA splicing map"[@ule2006]
Function
Master Splicing Regulator
NOVA1 regulates alternative splicing of a vast network of neuronal transcripts:
- Scope: HITS-CLIP and RNA-seq studies identified ~700 NOVA1-regulated alternative splicing events in mouse brain
- Target classes: Enriched for transcripts encoding synaptic proteins (pre- and post-synaptic), ion channels, cell adhesion molecules, and signaling proteins
- Mechanism: NOVA1 interacts with the spliceosome machinery, including U1 snRNP and core spliceosome components, to modulate splice site selection
Key Splicing Targets
NOVA1 regulates the splicing of transcripts critical for neuronal function:
| Target Gene | Regulated Event | Functional Consequence |
|-------------|----------------|----------------------|
| [GABA(A) receptor γ2](/genes/gabrg2) | Exon 9 (γ2S vs γ2L) | Modulates receptor trafficking and phosphorylation |
| [Glycine receptor α2](/genes/glra2) | Exon 3A vs 3B | Alters receptor kinetics and localization |
| [NMDA receptor NR1](/genes/grin1) | Exon 5, 21 (N1, C2') | Affects receptor conductance and trafficking |
| Agrin | Z exons | Controls neuromuscular junction formation |
| [Neuroligin 1](/genes/nlgn1) | Splice site B | Regulates excitatory synapse specificity |
| GIRK2 (Kir3.2) | Exon 1a/1b | Determines subcellular channel localization |
| Enabled (Enah) | EVH2 domain exon | Actin cytoskeleton regulation at synapses |
Synaptic Development and Function
NOVA1 is essential for proper synaptogenesis and synaptic transmission:
- Nova1 knockout mice die postnatally with motor neuron [apoptosis](/entities/apoptosis) and brainstem/spinal cord deficits
- NOVA1 regulates the splicing of adhesion molecules controlling synapse formation
- Alternative splicing of neurotransmitter receptors by NOVA1 tunes inhibitory synaptic transmission
- NOVA1 targets are enriched at both excitatory and inhibitory synapses[@ule2005]
Recent work has expanded NOVA1's functions beyond splicing:
- Alternative polyadenylation: NOVA1 regulates 3' UTR length of hundreds of neuronal transcripts, affecting mRNA stability and translation
- RNA localization: Binds 3' UTR YCAY elements to regulate dendritic mRNA transport
- Translational control: Modulates ribosome association of target mRNAs at synapses
Disease Associations
Paraneoplastic Opsoclonus-Myoclonus Ataxia (POMA)
NOVA1 was originally identified as the autoantigen in POMA:
- POMA patients develop antibodies against NOVA1 (anti-Ri antibodies) in the context of breast or lung cancer
- The autoimmune response destroys NOVA1-expressing neurons in the brainstem and cerebellum
- Clinical features: chaotic eye movements (opsoclonus), myoclonus, truncal ataxia, and encephalopathy
- Disease mechanism: loss of NOVA1-dependent splicing in affected neurons leads to synaptic dysfunction and cell death[@buckanovich1993]
Alzheimer's Disease
Dysregulated NOVA1 function contributes to splicing abnormalities in [Alzheimer's disease](/diseases/alzheimers-disease):
- Expression changes: NOVA1 protein levels are reduced in AD temporal [cortex](/brain-regions/cortex), correlating with disease severity
- Splicing alterations: Many NOVA1 target exons show altered inclusion levels in AD brain, including glutamate receptor and synaptic adhesion transcripts
- Tau interaction: NOVA1 splicing of [MAPT](/genes/mapt) (tau) pre-mRNA regulates exon 10 inclusion, influencing the 3R/4R tau ratio. NOVA1 loss leads to tau mis-splicing, connecting to [tauopathy](/mechanisms/tauopathy) mechanisms[@raj2018]
- Amyloid processing: NOVA1 regulates splicing of [APP](/genes/app) processing machinery, potentially affecting [amyloid-beta](/proteins/amyloid-beta) production
Parkinson's Disease
In [Parkinson's disease](/diseases/parkinsons-disease):
- NOVA1 expression declines in dopaminergic neurons of the substantia nigra
- Splicing of dopamine receptor (DRD2) and transporter (DAT/[SLC6A3](/genes/slc6a3)) mRNAs is NOVA1-dependent
- [Alpha-synuclein](/proteins/alpha-synuclein) aggregation disrupts nuclear NOVA1 function by sequestering it in cytoplasmic inclusions
- Altered NOVA1-dependent splicing of LRRK2 isoforms may modify PD risk
Amyotrophic Lateral Sclerosis
In [ALS](/diseases/amyotrophic-lateral-sclerosis):
- NOVA1 target transcripts show widespread splicing disruption in ALS spinal cord
- [TDP-43](/genes/tardbp) and NOVA1 co-regulate overlapping sets of neuronal exons; [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology indirectly affects NOVA1 targets
- [FUS](/entities/fus) interacts with NOVA1 to co-regulate RNA processing at synapses
- Motor neuron vulnerability in NOVA1 knockout mice recapitulates aspects of ALS
Epilepsy
- NOVA1 regulates splicing of GABA receptor subunits, which are critical for inhibitory neurotransmission
- Loss of NOVA1-dependent GABA receptor splicing disrupts inhibitory/excitatory balance
- Rare NOVA1 variants have been identified in patients with epileptic encephalopathy
Expression
Brain Distribution
NOVA1 shows a restricted expression pattern within the CNS:
- Hindbrain: Highest expression in the brainstem (especially ventral pons and medulla)
- Spinal cord: Ventral horn motor neurons and interneurons
- Subcortical regions: Hypothalamus, thalamus, basal ganglia
- Hippocampus: Moderate expression in CA1-CA3 and dentate gyrus
- Cerebral cortex: Lower expression, primarily in deeper layers
- Cerebellum: Purkinje cells and deep cerebellar nuclei
NOVA1 expression is complementary to [NOVA2](/genes/nova2), which predominates in the cerebral cortex and hippocampus, creating a combined coverage of all major brain regions.
Cell Type Specificity
- Exclusively expressed in neurons (not in glia)
- Enriched in inhibitory and motor neurons
- Absent from non-neural tissues (except in some cancers, where ectopic expression triggers autoimmunity)
Therapeutic Implications
Splicing-Correcting Therapies
NOVA1 dysfunction-associated diseases could benefit from RNA-targeted therapies:
Antisense oligonucleotides (ASOs): ASOs targeting specific NOVA1-regulated exons could correct mis-splicing events in neurodegeneration
Small molecule splicing modulators: Compounds that modulate NOVA1-dependent splice site selection
Gene therapy: AAV-mediated NOVA1 restoration in affected brain regionsBiomarker Applications
- NOVA1-dependent splicing patterns in CSF-derived RNA as biomarkers for neurodegenerative disease stage
- Altered ratios of NOVA1-regulated splice variants (e.g., [MAPT](/proteins/tau) exon 10 ratio) as disease indicators
Key Publications
[Buckanovich et al., Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein (1993)](https://pubmed.ncbi.nlm.nih.gov/8380164/)
[Ule et al., NOVA regulates brain-specific alternative splicing through an RNA map (2006)](https://pubmed.ncbi.nlm.nih.gov/16998473/)
[Raj & Bhatt, NOVA1-regulated RNA networks in brain aging and Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29959142/)
See Also
- [NOVA2](/genes/nova2) — NOVA alternative splicing regulator 2 (paralog)
- [TARDBP](/genes/tardbp) — TDP-43 RNA-binding protein (ALS/FTD)
- [FUS](/entities/fus) — Fused in sarcoma RNA-binding protein (ALS)
- [MAPT](/genes/mapt) — Microtubule-associated protein tau
- [RNA Splicing Defects](/mechanisms/rna-splicing-defects) — Splicing dysfunction in neurodegeneration
- [Spliceosome](/mechanisms/spliceosome) — Pre-mRNA splicing machinery
External Links
- [NCBI Gene: NOVA1](https://www.ncbi.nlm.nih.gov/gene/4857)
- [UniProt: P51513](https://www.uniprot.org/uniprot/P51513)
- [OMIM: 602157](https://omim.org/entry/602157)
- [GeneCards: NOVA1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=NOVA1)
References
[Buckanovich et al., Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system (1993) (1993)](https://pubmed.ncbi.nlm.nih.gov/8380164/)
[Ule et al., An RNA map predicting Nova-dependent splicing regulation (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16998473/)
[Jensen et al., Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability (2000) (2000)](https://pubmed.ncbi.nlm.nih.gov/10766236/)
[Ule et al., Nova regulates brain-specific splicing to shape the synapse (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/16341225/)
[Unknown, Raj & Bhatt, Integrative transcriptomic analysis reveals dysregulation of NOVA1-regulated RNA network in Alzheimer's disease brain (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29959142/)
[Unknown, Darnell RB, HITS-CLIP: panoramic views of protein-RNA regulation in living cells (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20603535/)
[Licatalosi et al., HITS-CLIP yields genome-wide insights into brain alternative RNA processing (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18978215/)